SCHEMBL3573776

SCHEMBL3573776

N#CCc1ccc(NC=C2C(=O)NC(=O)c3ccccc32)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.43
GSK3B P49841 1/20 0.41
PARP1 P09874 2/20 0.40
PARP2 Q9UGN5 1/20 0.40
PSD A5PKW4 2/20 0.39
CASP3 P42574 1/20 0.37
CASP2 P42575 1/20 0.37
CASP7 P55210 1/20 0.37
CASP6 P55212 1/20 0.37
CASP8 Q14790 1/20 0.37
ALDH1A1 P00352 5/20 0.36
PKM P14618 3/20 0.36
NPC1 O15118 2/20 0.36
THRB P10828 1/20 0.36
RAB9A P51151 1/20 0.36
MAPT P10636 3/20 0.35
HTT P42858 2/20 0.35
LMNA P02545 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
CRHBP P24387 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3573775 1.00 KMT2A (0.43) KMT2AGSK3BPARP1PARP2PSD
SCHEMBL4992920 0.88 MAPT (0.48) KMT2AALDH1A1PKMMAPTHTT
SCHEMBL4992915 0.88 MAPT (0.48) KMT2AALDH1A1PKMMAPTHTT
SCHEMBL3566338 0.87 PIK3CA (0.41) KMT2APSDCASP3ALDH1A1NPC1
SCHEMBL3566337 0.87 PIK3CA (0.41) KMT2APSDCASP3ALDH1A1NPC1
SCHEMBL3578966 0.85 ALDH1A1 (0.42) KMT2APARP1PSDCASP3ALDH1A1
SCHEMBL3564791 0.85 PTPRC (0.40) KMT2AGSK3BPARP1ALDH1A1NPC1
SCHEMBL3565384 0.85 PIK3CA (0.40) KMT2AALDH1A1NPC1THRBRAB9A
SCHEMBL3578969 0.85 ALDH1A1 (0.42) KMT2APARP1PSDCASP3ALDH1A1
SCHEMBL3564788 0.85 PTPRC (0.40) KMT2AGSK3BPARP1ALDH1A1NPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US claimed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US claimed
US-7713994-B2 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo,1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihyro-3 (2H)-isoquinolones and methods of use thereof WYETH LLC (US) 2010-05-11 US disclosed
EP-1963273-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITORS Wyeth a Corporation of the State of Delaware (US) 2008-09-03 EP disclosed
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof WYETH (US) 2008-04-10 US disclosed
WO-2007075783-A2 SUBSTITUTED ISOQUINOLINE-1,3(2H,4H)-DIONES, 1-THIOXO-1,4-DIHYDRO-2H-ISOQUINOLINE-3-ONES AND 1,4-DIHYDRO-3(2H)-ISOQUINOLONES AND USE THEREOF AS KINASE INHIBITOR WYETH (US) 2007-07-05 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080085890-A1 Substituted isoquinoline-1,3(2H,4H)-diones, 1-thioxo-1,4-dihydro-2H-isoquinoline-3-ones and 1,4-dihydro-3 (2H)-isoquinolones and methods of use thereof SULT1E1, RECQL, HAX1 KMT2A 1053/4885GSK3B 4189/4885PARP1 1048/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.